• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Keywords » antidepressant-augmentation

Items Tagged with 'antidepressant-augmentation'

ARTICLES

How to Prescribe Omega-3 Fatty Acids

March 4, 2022
Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Omega-3s are effective as augmentation of mood stabilizers in bipolar depression, and in some cases, they improve negative symptoms in early schizophrenia. The research is vast, but we narrow down when and how to use omega-3s in real-world practice.
Read More

How to Use SAMe in Clinical Practice

January 4, 2022
Garrett Rossi, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Garrett Rossi, MD. Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ. Dr. Rossi has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
SAMe is one of the few natural therapies that can hold its own against antidepressants. In this article, learn when and how to use it.
Read More

Light Therapy: Good for What Ails You?

September 28, 2021
Edmund S. Higgins, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Edmund S. Higgins, MD. Clinical associate professor, Psychiatry and Behavioral Sciences, Medical University of South Carolina. Dr. Higgins has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
The health benefits of light therapy are expanding its use beyond winter depression. Here we explore those promises and pitfalls, including ADHD, PTSD, bipolar depression, binge eating, sleep disorders, dementia, sexual dysfunction, traumatic brain injury, diabetes, and arthritis.
Read More

Psilocybin vs Escitalopram for Depression

September 10, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Psilocybin is inching its way toward FDA approval in depression, but will this trial from the New England Journal of Medicine help it along or set it back?
Read More

ECT Worked: Now What?

August 3, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Your patient has recovered from depression with ECT, but their chances of going back into it are high (80%). In this article, learn 3 ways to reduce that risk.
Read More

Antipsychotic Use Associated With Increased Risk of Mortality

March 11, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
The study is not without flaws, but it raises some concerns about the long term health-effects of antipsychotic augmentation.
Read More

The Psychopharmacology Algorithm Project

March 30, 2020
David Osser, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
David Osser, MDDavid Osser, MD

General Editor of the Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Residency Training Program and Associate Professor of Psychiatry at Harvard University. Dr. Osser has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression.
Read More

Getting Uncomfortable with Esketamine

January 13, 2020
Nolan Williams, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Nolan Williams, MDNolan Williams, MD

Director of the Brain Stimulation Lab and Interventional Psychiatry Clinical Research Program; Assistant Professor of Psychiatry at Stanford University, CA. Dr. Williams has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The FDA approval of esketamine (Spravalto) left some unanswered questions, including suicide, addiction, withdrawal, neurotoxicity, and bladder inflammation. Nolan Williams addresses those risks and looks at where esketamine fits among other options like TMS and ECT. Dr. Williams directs the Interventional Psychiatry Clinical Research Program and Brain Stimulation Lab at Stanford University.
Read More

Antipsychotic Maintenance: How Long is Enough?

January 13, 2020
Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Atypical antipsychotics can work quickly in mood disorders, but their long-term risks give us pause. When is it safe to discontinue them? The answer, it turns out, depends on whether we look to industry-supported or industry-independent trials.
Read More

Mirtazapine Augmentation: Running Low on Rocket Fuel

August 30, 2019
Thomas Jordan, MD and Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD and Chris Aiken, MD. Dr. Jordan and Dr. Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Dubbed “California Rocket Fuel” by Stephen Stahl, the combination of venlafaxine and mirtazapine seemed to hit all the right receptors. The hype may have gotten a little ahead of the evidence on this one, however, as three new studies reveal.

Read More
Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.